TNFAIP3 and classic Hodgkin lymphoma: Genomic gains of REL, which is encoded by the TNFAIP3 gene, an inhibitor of NF-κB activity, are present in approximately 30% of HL cases [31,32], and the gene is inactivated in approximately 40% of cHL cases [33].